# GenomicLens MD
## Autonomous Pharmacogenomic Clinical Decision Support

**Tagline:** *Turn genotype data into safer prescriptions — in seconds, not weeks.*

**Contact:** Faizan Masood | faizanmasood009@gmail.com

---

## Slide 1: The Problem — Prescribing Without Genomics Kills

**The status quo is blind prescribing.**

- **~2 million** adverse drug reactions (ADRs) per year in the US alone
- **>100,000 deaths** annually from properly prescribed medications — because the *genotype* wasn't checked
- **CPIC guidelines exist** for 500+ drug-gene pairs but are virtually unused at the point of care
- **Result:** A patient with a CYP2D6 ultra-rapid metabolizer phenotype gets standard-dose codeine → toxic morphine spike → respiratory arrest. This is documented. Avoidable. And routine.

**The gap isn't knowledge. It's integration.**

---

## Slide 2: The Solution — GenomicLens MD

**Multi-agent AI that checks every prescription against your genome before it's written.**

| What it does | How |
|---|---|
| Ingests patient genotype (CYP450 profiles) | FHIR-compatible, manual entry, or lab upload |
| Runs drug-gene check against CPIC rules | Deterministic engine + RAG-grounded knowledge |
| Spawns 3 specialist AI agents to debate | Pharmacologist, Geneticist, Clinician |
| Adjudicator synthesizes consensus | Risk level + alternative recommendation |
| Human gate requires clinician approval | Before any downstream action |

**Output:** A structured, auditable risk assessment with evidence citations, alternative therapies, and the full reasoning trace — in under 5 seconds.

---

## Slide 3: Technical Architecture

```
┌──────────────────────────────────────────────────┐
│                 HTTP Request                       │
└──────────┬───────────────────────────────────────┘
           ▼
┌──────────────────────┐    ┌─────────────────────┐
│  Deterministic Rules  │    │  ChromaDB RAG       │
│  pgx/rules.py         │◄───│  (CPIC guidelines,  │
│  (CPIC drug-gene map) │    │   FDA labels,       │
└──────────┬───────────┘    │   PharmGKB)         │
           │               └─────────────────────┘
           ▼
┌──────────────────────────────────────────────────┐
│          LangGraph Orchestrator                   │
├──────────────────────────────────────────────────┤
│  ┌──────────────┐  ┌──────────────┐  ┌─────────┐ │
│  │ Pharmacologist│  │ Geneticist   │  │Clinician│ │
│  │ (Groq/Llama 3)│  │ (Groq/Llama 3)│  │(Groq/Llama│ │
│  └──────┬───────┘  └──────┬───────┘  └────┬────┘ │
│         └─────────────────┼────────────────┘      │
│                           ▼                        │
│               ┌──────────────────┐                │
│               │   Adjudicator    │                │
│               │ (Consensus +     │                │
│               │  Fallback logic) │                │
│               └────────┬─────────┘                │
└────────────────────────┼──────────────────────────┘
                         ▼
┌──────────────────────────────────────────────────┐
│  Human Gate  (mandatory review) → Clinical Note   │
└──────────────────────────────────────────────────┘
```

**Technology stack:**
- **Orchestration:** LangGraph (stateful agent graphs)
- **Inference:** Groq (Llama 3 70B) — sub-200ms per agent
- **Vector Store:** ChromaDB (CPIC + FDA + PharmGKB corpus)
- **API:** FastAPI + Pydantic + JWT auth
- **Frontend:** Next.js 16 + Three.js (3D pathway viz)
- **Observability:** LangSmith tracing + drift monitoring

---

## Slide 4: Current Capabilities

### ✅ Deterministic CPIC Rule Engine
**7 drugs** with multi-enzyme cross-talk (CYP2D6, CYP2C19, CYP3A4):
codeine, tramadol, hydrocodone, oxycodone, pregabalin, duloxetine, clopidogrel

**4 synthetic patient profiles** spanning UM, PM, NM phenotypes

**Risk levels:** none → low → moderate → high → critical
**Flag threshold:** high/critical automatically flagged

### ✅ Multi-Agent Debate Panel
- **Pharmacologist:** Drug metabolism, PK/PD, prodrug activation, DDI potential
- **Geneticist:** CYP phenotype interpretation, allele function, genotype-phenotype correlation
- **Clinician:** Clinical lens — age, sex, indication, polypharmacy, comorbidities
- **Adjudicator:** Majority voting + severity scoring → consensus

### ✅ RAG Knowledge Base
**5 CPIC/FDA/PharmGKB documents** ingested into ChromaDB, semantic search across guidelines

### ✅ Tool Registry
5 tools: `query_drug_db`, `lookup_patient_history`, `search_knowledge`, `get_phenotype_info`, `calculate_egfr`

### ✅ Full Audit Trail
LangSmith tracing + drift monitoring comparing LLM vs. deterministic fallback outputs

### ✅ Frontend
Next.js 16 app with 3D metabolic pathway visualization

### ✅ Test Suite
**17 test files** covering rules, RAG, debate, tools, tracing, FHIR, API perimeter, n-of-1, therapy generation, pipeline, review flow

---

## Slide 5: Validation — The Safety-First Architecture

Every AI recommendation is checked against **deterministic guardrails** before reaching the clinician.

```
LLM Agent Output
      │
      ▼
┌─────────────────────┐
│  Drift Monitor       │  ← Compares LLM vs fallback
│  (LangSmith + custom)│    Flags risk_level deltas,
└──────────┬──────────┘    flagged mismatches
           ▼
┌─────────────────────┐
│  Deterministic       │  ← Hardcoded CPIC rules
│  Guardrail Engine    │    Always wins in conflict
│  (pgx/rules.py)      │
└──────────┬──────────┘
           ▼
┌─────────────────────┐
│  Human Gate          │  ← Mandatory approval
│  (Clinician Review)  │    No downstream action
└──────────┬──────────┘    without sign-off
           ▼
      Clinical Note
```

**Key principle:** The LLM *advises*, the rules *constrain*, the human *decides*.

---

## Slide 6: The Market Opportunity

### Primary: Pharmacogenomic CDS in Health Systems

| Metric | Value |
|---|---|
| Global PGx market (2024) | $9.6B |
| CAGR | 11.5% |
| US hospitals with PGx programs | <5% |
| CPIC guidelines published | 100+ |
| Genotyped patients with no CDS | >90% |

### Secondary: Rare Disease / N-of-1 Therapy
- **300M** people globally with rare diseases
- **Personalized oncology** vaccines require patient-specific design
- **Current process:** Manual, multi-month, prohibitively expensive

### Target Customers
1. **Hospital systems** with existing genomic programs (UAE Genome, M42, Cleveland Clinic Abu Dhabi)
2. **Clinical research organizations** running PGx trials
3. **Boutique clinics** offering concierge genomic medicine

---

## Slide 7: Market Traction & Milestones

### ✅ Completed (4 Phases)

| Phase | Component | Status |
|---|---|---|
| 1 | RAG knowledge base + ChromaDB ingestion | Done |
| 2 | Tool registry + function calling framework | Done |
| 3 | Multi-agent debate panel (3 specialists + adjudicator) | Done |
| 4 | LangSmith tracing + drift/hallucination monitoring | Done |

**17 passing tests** across all subsystems

### 🔜 Next Milestones (Sprint A)

| Sprint | Scope | Timeline |
|---|---|---|
| **A** | Expanded formulary → SSRIs, Statins, NSAIDs (~50+ drugs) | Q3 2026 |
| **B** | Reasoning Trace UI (debate transparency in frontend) | Q3 2026 |
| **C** | Episodic memory (learn from clinician corrections) | Q4 2026 |
| **D** | Real bioinformatics (ViennaRNA, BLAST) | Q4 2026 |
| **E** | Adherence lab (patient simulator + check-in) | Q1 2027 |

---

## Slide 8: Competitive Landscape

| Feature | **GenomicLens MD** | YouScript | Genomind | Epic PGx | 23andMe Reports |
|---|---|---|---|---|---|
| Multi-agent debate | ✅ | ❌ | ❌ | ❌ | ❌ |
| Deterministic guardrails | ✅ | ✅ | ✅ | ❌ | ❌ |
| N-of-1 therapy pipeline | ✅ | ❌ | ❌ | ❌ | ❌ |
| Auditable reasoning trace | ✅ | ❌ | ❌ | ❌ | ❌ |
| Model-agnostic (Groq/GPT/Claude) | ✅ | ❌ | ❌ | ❌ | ❌ |
| EHR integration (FHIR) | ✅ | ✅ | ❌ | ✅ | ❌ |
| RAG-grounded guidelines | ✅ | ❌ | ❌ | ❌ | ❌ |
| Open-source core | ✅ | ❌ | ❌ | ❌ | ❌ |

**Key differentiator:** GenomicLens MD is the only system where AI agents are *challenged by other AI agents* with deterministic fallback. Every other tool is either a static lookup or an opaque LLM wrapper.

---

## Slide 9: Team

**Faizan Masood** — Solo Founder & Full-Stack AI Engineer

| Domain | Expertise |
|---|---|
| Agent Orchestration | LangGraph, multi-agent debate patterns, tool use |
| AI/ML | Groq API, LLM integration, RAG, ChromaDB |
| Backend | FastAPI, PostgreSQL, JWT auth, FHIR data models |
| Frontend | Next.js, React, Three.js 3D visualization |
| Observability | LangSmith tracing, drift monitoring, structured logging |
| DevOps | Task queue patterns, async pipelines, rate limiting |
| Bioinformatics | N-of-1 therapy generation, RNA sequence design (in progress) |

**Status:** Bootstrapped, ~12 months runway

---

## Slide 10: Regulatory & Data Strategy

**Current:**
- Synthetic demo data only — zero PHI exposure
- Discovery/Research stage — pre-clinical
- No clinical trials, no patient data processed

**Near-term (12 months):**
- Submit FDA Pre-Submission (Q-sub) for 510(k) pathway
- Deploy shadow-mode pilot with synthetic data at 1 UAE hospital
- Formalize ISO 14971 risk management plan
- Implement PHI de-identification layer (local NLP scrubber)

**Long-term:**
- 510(k) clearance for Software as a Medical Device (Class II)
- SMART-on-FHIR write-back to EHRs (Epic, Cerner)
- Full HIPAA/ADHICS compliance with encryption-at-rest, BAA, audit logging

---

## Slide 11: Ask

**What we need to reach pilot-ready status (12 months):**

| Need | Purpose |
|---|---|
| **$150K seed funding** | 1 clinical domain expert hire + 1 full-stack engineer + infra |
| **Hospital pilot partner** | Shadow-mode deployment with anonymized retrospective data |
| **Regulatory consultant** | FDA 510(k) pre-submission dossier |
| **Hub71 ecosystem** | DOH/M42 introductions, talent pipeline, co-working |

**Use of funds:**
- 40% — Clinical domain expertise (pharmacist + regulatory)
- 30% — Engineering (frontend + bioinformatics integration)
- 20% — Cloud infrastructure & tooling
- 10% — Legal & compliance

---

## Slide 12: Summary

> **GenomicLens MD turns pharmacogenomic data from a lab report into an autonomous clinical safety net — using multi-agent AI debate, deterministic CPIC guardrails, and mandatory human oversight.**

- ✅ Working prototype with 4 integrated phases
- ✅ 17-pass test suite across all subsystems
- ✅ 7-drug formulary + 4 patient profiles
- ✅ Multi-agent debate with drift monitoring
- ✅ Next.js frontend with 3D pathway visualization
- ✅ Clear regulatory path to 510(k)

**Next step:** Expand formulary to 50+ drugs and deploy shadow-mode pilot with a UAE health system.

---

*Built with LangGraph · Groq · ChromaDB · FastAPI · Next.js · Three.js*
